Methotrexate-mediated tumor-targeting metal organic framework pharmaceutical composition as well as preparation method and application thereof
The invention discloses a methotrexate-mediated tumor-targeted metal organic framework pharmaceutical composition as well as a preparation method and application of the methotrexate-mediated tumor-targeted metal organic framework pharmaceutical composition. According to the preparation method, methotrexate which has anti-tumor activity and an active targeting function is taken as a material and is covalently bound with PEG (Polyethylene Glycol) to obtain the MTX-PEG-COOH tumor targeting drug conjugate. And modifying the methotrexate into a metal organic framework ZIF-8 through the interaction of positive and negative charges, so as to prepare the methotrexate-mediated tumor-targeted metal organic framework pharmaceutical composition (MTX/ZIF-8). The MTX/ZIF-8 is simple in preparation process, low in cost, good in repeatability and high in batch-to-batch consistency. The MTX/ZIF-8 can be used for a tumor targeted drug delivery system, and the chemotherapeutic drug can be encapsulated by a simple one-step encapsulation method, so that the MTX/ZIF-8 has the advantages of high drug loading rate, good stability and responsive drug release. In addition, when a chemotherapeutic drug is entrapped by MTX/ZIF-8, the advantage of dual-mechanism synergistic anti-tumor can be exerted, so that the enhanced anti-tumor effect is realized..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 26. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
KO JONG-HO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-26, Last update posted on www.tib.eu: 2024-03-25, Last updated: 2024-03-29 |
|---|
| Patentnummer: |
CN117442750 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA002785269 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA002785269 | ||
| 003 | DE-627 | ||
| 005 | 20240329160652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA002785269 | ||
| 035 | |a (EPA)CN117442750 | ||
| 035 | |a (EPA)89591577 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a KO JONG-HO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Methotrexate-mediated tumor-targeting metal organic framework pharmaceutical composition as well as preparation method and application thereof |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-26, Last update posted on www.tib.eu: 2024-03-25, Last updated: 2024-03-29 | ||
| 520 | |a The invention discloses a methotrexate-mediated tumor-targeted metal organic framework pharmaceutical composition as well as a preparation method and application of the methotrexate-mediated tumor-targeted metal organic framework pharmaceutical composition. According to the preparation method, methotrexate which has anti-tumor activity and an active targeting function is taken as a material and is covalently bound with PEG (Polyethylene Glycol) to obtain the MTX-PEG-COOH tumor targeting drug conjugate. And modifying the methotrexate into a metal organic framework ZIF-8 through the interaction of positive and negative charges, so as to prepare the methotrexate-mediated tumor-targeted metal organic framework pharmaceutical composition (MTX/ZIF-8). The MTX/ZIF-8 is simple in preparation process, low in cost, good in repeatability and high in batch-to-batch consistency. The MTX/ZIF-8 can be used for a tumor targeted drug delivery system, and the chemotherapeutic drug can be encapsulated by a simple one-step encapsulation method, so that the MTX/ZIF-8 has the advantages of high drug loading rate, good stability and responsive drug release. In addition, when a chemotherapeutic drug is entrapped by MTX/ZIF-8, the advantage of dual-mechanism synergistic anti-tumor can be exerted, so that the enhanced anti-tumor effect is realized. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a WU HAO |4 aut | |
| 700 | 0 | |a HUANG WEI |4 aut | |
| 700 | 0 | |a LIU YANHONG |4 aut | |
| 700 | 0 | |a ZHAO HEMING |4 aut | |
| 700 | 0 | |a KIM MYEONG-HEE |4 aut | |
| 700 | 0 | |a CHEN LIQING |4 aut | |
| 700 | 0 | |a WANG QIMING |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 26. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:26 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89591577/publication/CN117442750A1?q=CN117442750 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 26 |c 01 | ||